Targeting proteins to improve treatment for aggressive brain cancer
Targeting scaffolding proteins to disrupt radioresistance in glioblastoma
This study is looking at ways to make radiation therapy work better for people with glioblastoma, a tough type of brain cancer, by targeting the special cells that help the tumor survive and resist treatment.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Upstate Medical University NIH-funded |
| Lab location | 1 site (Syracuse, United States) |
| Project ID | NIH-10975997 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain cancer that often becomes resistant to standard treatments. The project aims to disrupt the survival mechanisms of glioblastoma stem-like cells, which are responsible for the tumor's resilience. By targeting specific cell-scaffolding proteins that these cells rely on, the researchers hope to enhance the effectiveness of radiation therapy. This innovative approach seeks to create vulnerabilities in the cancer cells, potentially leading to better treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are experiencing treatment resistance.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting similar cellular mechanisms in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Syracuse, United States
- Upstate Medical University — Syracuse, United States (Active)
Researchers
- Principal investigator: Viapiano, Mariano Sebastian — Upstate Medical University
- Study coordinator: Viapiano, Mariano Sebastian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.